Gema Diagnostics

About This Project

Gema is developing noninvasive human oocyte and embryo selection methods to fundamentally improve the clinical outcomes of in vitro fertilization (IVF). Their technology originates from work conducted at the Michigan State University Cellular Reprogramming Laboratory, the Yale University School of Medicine, and the University of Oxford Institute of Reproductive Sciences under the leadership of Dr. Jose Cibelli and Dr. Dagan Wells, two of the world’s leading scientists in reproductive technologies.